Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: Results of the French NBL 90 study

European Journal of Cancer

Volumn 33, Issue 12, 1997, Pages 1917-1922

  Rubie, H ^a   Delattre, O ^b   Hartmann, O ^b   Combaret, V ^b   Michon, J ^b   Benard J ^b   Peyroulet, M C ^a   Plantaz, D ^c   Coze, C ^d   Chastagner, P ^e   Baranzelli, M C ^b   Frappaz, D ^b   Lemerle, J ^b   Sommelet, D ^e  

^a CHU PURPAN   (France)

^b I Curie ^*  (France)

^c CHU La Tronche and University   (France)

^d TIMONE HOSPITAL   (France)

^e CHU NANCY BRABOIS   (France)

Author keywords

Chromosome 1p; MYCN; Neuroblastoma

Indexed keywords

CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHROMOSOMAL LOCALIZATION; CHROMOSOME 1P; CHROMOSOME LOSS; CONFERENCE PAPER; DIAGNOSTIC VALUE; FEMALE; GENE AMPLIFICATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE;

ABDOMINAL NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; GENES, MYC; HUMANS; INFANT; INFANT, NEWBORN; MALE; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0031418166     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00295-5     Document Type: Conference Paper

References (30)

1. Bernstein ML, Leclerc JM, Bunin G, et al. A population-based study of neuroblastoma incidence, survival, and mortality in North America. J Clin Oncol 1992, 10, 323-329.
2. Rosen E. M., Cassady J. R., Frantz C. N., et al. Neuroblastoma: The Joint Center for Radiation Therapy/Dana Farber Cancer Institute/Children's Hospital experience. J Clin Oncol. 2:1984;719-732.
3. Berthold F., Brandeis W. E., Lampert F. Neuroblastoma: diagnostic advances and therapeutic results in 370 patients. Monogr Paediatr. 18:1986;206-223.
4. Evans AE, Albo V, D'Angio GJ, et al. Factors influencing survival of children with non metastatic neuroblastoma. Cancer 1976, 38, 661-666.
5. Le Tourneau J. N., Bernard J. L., Hendren W. H., Carcassonne M. Evaluation of the role of surgery in 130 patients with neuroblastoma. J Pediatr Surg. 20:1985;244-249.
6. De Bernardi B, Rogers D, Carli M, et al. Localized neuroblastoma. Surgical and pathological staging. Cancer 1987, 60, 1066-1072.
7. Evans AE, D'Angio GH, Koop C, et al. The role of multimodal therapy in patients with local and regional neuroblastoma. J Pediatr Surg 1984, 19, 77-80.
8. Joshi VV, Cantor A, Altshuler G, et al. Recommendations for modification of terminology of neuroblastic tumors and prognostic significance of Shimada classification: a clinicopathologic study of 213 cases from the Pediatric Oncology Group. Cancer 1992, 69, 2183-2196.
9. Zelter P. M., Marangos P. J., Evans A. E., Schneider S. L. Serum neuron specific enolase in children with neuroblastoma. Relationship to stage and disease course. Cancer. 57:1986;1230-1234.
10. Hann H. W. L., Levy H. M., Evans A. E. Serum ferritin as a guide to therapy in neuroblastoma. Cancer Res. 40:1980;1411-1413.
11. Shuster JH, McWilliams NB, Castelberry R, et al. Serum lactate dehydrogenase in childhood neuroblastoma. Am J Clin Oncol 1992, 15, 295-303.
12. Evans A. E., D'Angio G. J., Propert K., Anderson J., Hann H. W. L. Prognostic factors in Neuroblastoma. Cancer. 59:1987;1853-1859.
13. Look A. T., Hayes F. A., Nitschke R., McWilliams N. B., Green A. A. Cellular DNA content as predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med. 311:1984;231-235.
14. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of N-Myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985, 318, 111-116.
15. Fong CT, White PS, Peterson K, et al. Loss of heterozyosity for chromosome 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res 1992, 52, 1780-1785.
16. Brodeur GM, Azar C, Brother M, et al. Neuroblastoma: effect of genetic factors on prognosis and treatment. Cancer 1992, 70, 1685-1694.
17. Joshi VV, Cantor AB, Brodeur GM, et al. Correlations between morphologic and other prognostic markers of neuroblastoma. Cancer 1993, 71, 3173-3181.
18. Gilbert F., Balaban G., Moorhead P., Bianchi D., Schlesinger H. Abnormalities of chromosome 1 in human neuroblastoma tumors and cell lines. Cancer Genet Cytogenet. 7:1982;33-42.
19. Michon J, Delattre O, Zucker JM, et al. Prospective evaluation of Nmyc amplification and deletion of the short arm of chromosome 1 in neuroblastoma tumours: a single institution study. 6th Symp. Advances in Neuroblastoma Research,13-15.05.93, Philadelphia. Philadelphia, 1993.
20. Gehring M., Berthold F., Edler L., Schwab M., Amler L. C. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res. 55:1995;5366-5369.
21. Caron H, Van Sluis P, De Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996, 334, 225-230.
22. Mäkinen J. Microscopic patterns as a guide to prognosis of neuroblastoma in childhood. Cancer. 29:1972;1637-1646.
23. American Joint Committee. Neuroblastoma. In Beahrs OH, Myers MH, eds. Manual of Staging of Cancer. Philadelphia, Lippincott, 1983, 237-239.
24. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the International Criteria for Neuroblastoma Diagnosis, Staging and Response to Treatment. J Clin Oncol 1993, 11, 1466-1477.
25. Peter M, Michon J, Vielh P, et al. PCR assay for chromosome 1p deletion in small neuroblastoma samples. Int J Cancer 1992, 52, 544-548.
26. Schleiermacher G, Peter M, Michon J, et al. A multiplex PCR assay for routine evaluation of deletion of the short arm of chromosome 1 in neuroblastoma. Eur J Cancer 1995, 31A, 535-538.
27. Rubie H, Hartmann O, Michon J, et al. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. J Clin Oncol 1997, 15, 1171-1182.
28. Cheng NC, Van Roy N, Chan A, et al. Deletion mapping in neuroblastoma cell lines suggests two distinct tumour suppressor genes in the 1p 35-36 region, only one of which is associated with N-Myc amplification. Oncogene 1995, 10, 291-297.
29. Ambros P, Ambros IM, Strehl S, et al. Regression and progression in neublastoma: does genetics predict tumor behaviour? Eur J Cancer 1995, 31A, 510-516.
30. Christiansen H., Sahin K., Berthold F., et al. Comparison of DNA Aneuploïdy, Chromosome 1p abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma. Eur J Cancer. 31A:1995;541-544.